NCT04746612 - First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 8, 2021

Primary Completion Date

March 24, 2023

Study Completion Date

March 24, 2023

Conditions

Advanced Solid Tumors

Interventions

DRUG

HH30134

HH30134 administered orally on a continuous once daily(QD) in patients with advanced solid tumors

Trial Locations (4)

Blacktown Hospital, Blacktown

Scientia Clinical Research, Randwick

Sun Yat-sen University Cancer Center, Guangzhou

Fudan University Zhongshan Hospital, Shanghai